Fibronectin and factor XIII play a major role in blood coagulation cascade and contribute to wound healing and phagocytic function of macrophages. Spinal cord injured (SCI) patients with end-stage renal disease (ESRD) have been shown to exhibit a variety of coagulation abnormalities, a high incidence of infection and poor healing pressure ulcers. Earlier studies in SCI patients with no discernible renal disease revealed a marked rise in plasma fibronectin in patients with fast healing pressure ulcers.
disease (ESRD) (Vaziri et al., 1985 (Vaziri et al., -A, 1985 (Vaziri et al., -B, 1986 (Vaziri et al., , 1987 . In addition, a great majority of SCI-ESRD patients exhibit poor healing pressure ulcers as well as a variety of acute and chronic infections involving the urinary tract and other systems (Vaziri et al., 1982) . In a recent study of SCI patients without renal failure harboring pressure ulcers, we have found that a rise in plasma fibronectin concentration signifies rapid healing while lack of fibronectin elevation denotes a poor healing process (Vaziri et al., 1990) . In this study we determined plasma levels of fibronectin and factor XIII in a group of SCI men with ESRD and pressure ulcers.
Patients, materials and methods
Thirteen men with longstanding SCI and ESRD, 36 to 64 years of age, were studied. The level and duration of spinal cord injury varied from Cz-Ls and 6 to 63 years respectively. The aetiology of renal disease was multifactorial and consisted of chronic pyelonephritis, reflux nephropathy, secondary amyloidosis, urolithiasis, and hypertensive nephrosclerosis. Patients with significant liver disease, sepsis, acute intercurrent illnesses, disseminated intravascular coagulation and those consuming anticoagulants or other drugs known to affect the blood coagulation system were excluded from the study. All patients had chronic urinary tract infections and decubitus ulcers.
The duration of haemodialysis therapy ranged from 1 week to 8 years. Patients were dialysed for 3 to 4 hours three times weekly using a parallel-plate or hollow fiber cellulosic dialyser, a conventional acetate-buffered dialysate, and a single pass dialysate delivery system. Access to the blood stream was provided by surgically created Cimino arteriovenous fistulas or most commonly polytetrafluoroethylene (PTFE) grafts. Dialysis was performed under systemic anticoagulation using heparin 4000 to 7000 units in 4 divided doses.
Dietary restrictions were limited to water, sodium and potassium intakes as needed. No protein or caloric restrictions were imposed. Aluminum carbonate was prescribed as a phosphate binder and was taken with meals to control hyperphosphatemia. Multi-vitamins and folic acid were given to prevent deficiency states. Oral or parenteral iron preparations were employed in patients with iron deficiency. Blood transfusions were used in patients with severe symptomatic anemia unresponsive to other modalities. Pressure ulcers were managed as described previously (Eltorai and Chung, 1977) .
Control group
The control group consisted of 15 healthy men aged 25 to 45 years. They had normal prothrombin time (PT), partial thromboplastin time (PTT) and no evidence of coagulopathies, liver disease, renal, neurological or other disorders, and were not receiving any drugs including those known to affect the blood coagulation system.
Blood samples
Blood samples were drawn from the blood access site shortly before and after dialysis in SCI-ESRD patients. Free-flowing venous blood samples were obtained by venipuncture from the normal control group. Plastic syringes were used in all instances and samples were immediately transferred to plastic tubes containing 0' 1 molar sodium citrate solution (blood/citrate = 9/ 1, volume). The citrate anti coagulated blood was promptly centrifuged at 2000 X g for 20 minutes and plasma separated and stored at -70°C in multiple small plastic tubes until assayed.
I ntemal standard
The internal standard used was assayed coagulation reference plasma (ARP) which was obtained from Helena Laboratories (Beaumont, Texas). ARP was prepared from a pool of fresh citrated plasma from healthy, non-smoking men aged 20 to 40 years. The pool was buffered and lyophilised to ensure stability of all plasma constituents.
Immunological assays
Monospecific antisera produced in rabbits against purified human fibronectin and factor XIII a-subunit were used in respective assays employing electroimmuno diffusion. A standard curve was constructed with each assay session using several dilutions of the reference standard. The concentration of each protein was determined by extrapolation using the standard curve.
Data presentation and analysis
All data are given as mean ± SD and are expressed as per cent of the values found in the ARP standard. Student's t-test and regression analysis were employed as appropriate, and p-values equal to or less than 0'05 were considered statistically significant.
Results
The mean value for plasma fibronectin concentration obtained in the SCI-ESRD group prior to dialysis (106 ± 52%) was not significantly different from that observed in the normal control group (99 ± 14%). Plasma fibronectin concentration obtained after dialysis (108 ± 33%) did not significantly differ from that observed before dialysis. Likewise, mean plasma factor XIII concentration obtained pre dialysis (128 ± 57%) was not significantly different from that of the control group (107 ± 19%). However, marked interindividual variations (48% to 308%) were noted in factor XIII levels in the SCI-ESRD patients. As with fibronectin, haemodialysis did not significantly change plasma factor XIII concentraiton (122 ± 30%, post-dialysis).
Discussion
Fibronectin is a nearly ubiquitous component of the body and plays a number of important functions related to haemostasis, tissue remodelling during embryo genesis and wound healing (Mosher, 1980 (Mosher, , 1987 . In addition, fibronectin serves as a non-specific opsonin, thereby facilitating the removal by macrophages of the circulating micoraggregates, especially those of self-associating proteins, e.g. fibrin, collagen and actin. It is a substrate for thrombin, plasmin and activated factor XIII (F-XlIIa). F-XIIIa catalyses the crosslinking of alpha and gamma chains of fibrin and as such contributes to the stability and strength of the thrombus. In addition, F-XlIIa promotes crosslinking of fibrin to fibronectin and fibronectin to collagen in the vessel wall and connective tissue. This results in firm anchoring of the clot to the site of injury. Moreover, fibronectin and factor XIII appear to enhance migration and proliferation of fibroblast which culminate in organisation of clot, wound repair and the healing process (Vaheri, 1983) .
In a recent study of SCI patients without discernible renal disease, we found an association between a patient's ability to attain a significant rise in plasma fibronectin and rapid healing of pressure ulcers. In contrast, failure to raise plasma fibronectin was associated with the presence of poor healing ulcers. In addition, we found no significant difference in plasma fibronectin concentration between normal able-bodied controls and SCI controls who were otherwise healthy. 
